Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.
Quon H, Cheung PC, Loblaw DA, Morton G, Pang G, Szumacher E, Danjoux C, Choo R, Thomas G, Kiss A, Mamedov A, Deabreu A.
Quon H, et al. Among authors: pang g.
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):898-905. doi: 10.1016/j.ijrobp.2010.11.003. Epub 2011 Jan 14.
Int J Radiat Oncol Biol Phys. 2012.
PMID: 21237581
Clinical Trial.